Officer Files Intent to Sell Nearly $800K in Rapport Therapeutics Stock
Summary
An officer of Rapport Therapeutics, Krishnaswamy Yeleswaram, has filed a Form 144 indicating intent to sell approximately $800,000 worth of common stock, continuing a pattern of pre-planned sales.
Key Events
-
Officer Files Intent to Sell Shares
Krishnaswamy Yeleswaram, an officer of Rapport Therapeutics, filed a Form 144 to sell 20,225 shares of common stock.
-
Significant Value of Proposed Sale
The proposed sale has an approximate market value of $799,696.50.
-
Part of Pre-Planned Program
The sales are indicated to be part of a 10b5-1 trading plan adopted on December 10, 2025.
-
Ongoing Insider Sales Pattern
This filing is part of a series of Form 144 filings by the same officer and contributes to a broader pattern of insider distribution over the last 90 days.
Analysis
This Form 144 indicates an officer's intent to sell a notable amount of company stock, valued at approximately $800,000. While the sale is part of a pre-planned 10b5-1 program, which suggests it's not a discretionary signal of lack of confidence, it still represents a reduction in insider holdings. This filing continues a recent pattern of Form 144 filings from the same officer, as well as other insider selling activity observed over the past 90 days. Investors should monitor actual sales reported on Form 4 to track the execution of these planned dispositions.
At the time of this filing, RAPP was trading at $39.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $7.73 to $42.27. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.